AJMC May 8, 2021
Biomarkers are being used in patients with cancer to target treatments that will work best. Interviews with OncLive® highlight how biomarkers are being used in colorectal and bladder cancer.
As cancer therapies become more targeted, biomarkers are an increasingly important tool to help understand a patient’s individual cancer and identify the treatments that will work best.
For instance, in colorectal cancer, approximately 40% of patients have KRAS wild-type disease, and established therapies such as cetuximab and panitumumab are effective, Atrayee Basu-Mallick, MD, a medical oncologist at Sidney Kimmel Cancer Center, and clinical assistant professor at the Thomas Jefferson University, recently told OncLive®.
On the other hand, approximately 8% of patients with colorectal cancer have a BRAF mutation, and the median...
Today's Sponsors
Today's Sponsor